Post-COVID syndrome is increasingly recognized as a new clinical entity in the context of
SARS-CoV-2 infection. Symptoms persisting for more than three weeks after the diagnosis of …

Background Hydroxychloroquine or chloroquine with or without azithromycin have been
widely promoted to treat coronavirus disease 2019 (COVID-19) following early in vitro …

Introduction: COVID-19 presents benign forms in young patients who frequently present with
anosmia. Infants are rarely infected, while severe forms occur in patients over 65 years of …

Approximately 9 months of the severe acute respiratory syndrome coronavius-2 (SARS-CoV-
2 [COVID-19]) spreading across the globe has led to widespread COVID-19 acute …

The SARS-CoV-2 virus spreading across the world has led to surges of COVID-19 illness,
hospitalizations, and death. The complex and multifaceted pathophysiology of life …

Background: The present study aimed to determine the global prevalence of anosmia and
dysgeusia in coronavirus disease 2019 (COVID-19) patients and to assess their association …

Objectives Describe and evaluate the outcome of COVID patient without shortness of breath
Design and methods We retrospectively collected data from COVID-19 patients diagnosed …

Hydroxychloroquine (HCQ) has been largely used and investigated as therapy for COVID-
19 across various settings at a total dose usually ranging from 2400 mg to 9600 mg. In …

Over the past 16 years, three coronaviruses (CoVs), severe acute respiratory syndrome CoV
(SARS-CoV) in 2002, Middle East respiratory syndrome CoV (MERS-CoV) in 2012 and …

Background The objective of this study was to better understand the factors associated with
the heterogeneity of in-hospital COVID-19 morbidity and mortality across France, one of the …